Drugs / Fibrocaps
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01256190 | Dec 2010 → Sep 2011 | — | Mallinckrodt | Completed | Met primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT02284256 | Nov 2014 → Aug 2015 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01527357 | May 2012 → Apr 2013 | — | Mallinckrodt | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrocaps | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01256190 ↗ |
| Known as | PRO-0601 | “Other Names: * Raplixa * PRO-0601 * Fibrin sealant” NCT02284256 ↗ |
| Modality | Protein / enzyme biologic | “human thrombin and fibrinogen topical powder” NCT01256190 ↗ |
| Route | Topical | “Topical Fibrocaps powder followed by application of gelatin sponge” NCT01256190 ↗ |